Watchdog criticises drug company for misleading promotional materialBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b5618 (Published 22 December 2009) Cite this as: BMJ 2009;339:b5618
- Adrian O’Dowd
A watchdog has criticised the drug company Ferring for five breaches of the United Kingdom’s drug advertising code, accusing it of misleading promotion of one of its products that omitted information about possible side effects.
Patients were also wrongly led to believe that they should ask their health professional to prescribe the gonadotrophin releasing hormone antagonist degarelix (sold as Firmagon), used to treat advanced prostate cancer, said the Prescription Medicines Code of Practice Authority in its newly issued ruling. The authority regulates the advertising code of the UK’s drug company representative body, the Association of the British Pharmaceutical Industry.
Ferring Pharmaceuticals employed a press relations agency to promote degarelix. It supplied an approved press release about the launch of degarelix to give to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial